Semax

Semax is a synthetic heptapeptide. It is an ACTH(4-7) fragment with a Pro-Gly-Pro extension that stabilizes it. Russian researchers developed it.

Semax increases BDNF. It sensitizes dopaminergic neurons. Reports describe a neuroprotective effect.

Evidence tier: clinical, in Russia.

Russian clinical use covers stroke recovery and disorders of cognition and the optic nerve. Semax sits on Russia's Essential Drugs List.

Some human studies measure network change and cognition. Those studies are small and regionally concentrated.

Evidence limit. Contemporary Western trial evidence is limited.

Russian clinical use gives Semax as an intranasal spray.

Neither the FDA nor the EMA sanctions a dose.

The intranasal route gives direct access to the central nervous system.

Sources do not document interactions well.

Compare with Selank.

Reported effects are nasal irritation and headache. A late dose can disrupt sleep.

No validated biomarker exists in Western practice.

Russia approves Semax. Neither the FDA nor the EMA approves it.

At the July 2026 PCAC meeting the FDA proposed not to add Semax to the 503A bulks list. Read the PCAC July 2026 outcome.

WADA probably prohibits it under S0.